FDA OKs Perioperative Immunotherapy for Head and Neck Cancer

(MedPage Today) — The FDA approved pembrolizumab (Keytruda) for patients with PD-L1-positive resectable locally advanced head and neck squamous cell carcinoma as neoadjuvant monotherapy, continued as adjuvant therapy plus radiotherapy with or…

Source link : https://www.medpagetoday.com/hematologyoncology/othercancers/116058

Author :

Publish date : 2025-06-13 14:51:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
				1	2	3
4	5	6	7	8	9	10
11	12	13	14	15	16	17
18	19	20	21	22	23	24
25	26	27	28	29	30	31

FDA OKs Perioperative Immunotherapy for Head and Neck Cancer

No Reason Not to Treat Migraine

Have You No Sense of Decency, Secretary Kennedy?

Related Posts

Combination Therapy for AMD Fails to Improve Vision Versus Single Drug

Questions Abound About Treating AMD, Geographic Atrophy at the Same Time

Which Physicians Have a Higher Mortality Risk?

HPV and Skin Cancer; Polygenic Risk Score for Obesity; Rare Flu Complication in Kids

War Is a Global Health Catastrophe

An Ohio Couple Welcomes a Baby Boy From a Nearly 31-Year-Old Frozen Embryo

Combination Therapy for AMD Fails to Improve Vision Versus Single Drug

Questions Abound About Treating AMD, Geographic Atrophy at the Same Time

Which Physicians Have a Higher Mortality Risk?

HPV and Skin Cancer; Polygenic Risk Score for Obesity; Rare Flu Complication in Kids

War Is a Global Health Catastrophe

An Ohio Couple Welcomes a Baby Boy From a Nearly 31-Year-Old Frozen Embryo

Brisk Walking May Help You Live Longer

Major Medical Groups Pushed Out of Role Supporting CDC’s Vaccine Advisors

Categories

Archives